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Objective
• To compare the eﬀectiveness of robot-assisted and standard
laparoscopic prostatectomy.
Methods
• A care pathway was described.
• We performed a systematic literature review based on a
search of Medline, Medline in Process, Embase, Biosis,
Science Citation Index, Cochrane Controlled Trials Register,
Current Controlled Trials, Clinical Trials, WHO
International Clinical Trials Registry and NIH Reporter, the
Health Technology Assessment databases, the Database of
Abstracts of Reviews of Eﬀects, and relevant conference
abstracts up to 31st October 2010). Additionally, reference
lists were scanned, an expert panel consulted, and websites
of manufacturers, professional organisations, and regulatory
bodies were checked.
• We selected randomised controlled trials (RCTs) and
non-randomised comparative studies, published after 1st
January 1995, including men with localised prostate cancer
undergoing robot-assisted or laparoscopic prostatectomy
compared with the other procedure or with open
prostatectomy. Studies where at least 90% of included men
had clinical tumour stages T1 to T2 and which reported at
least one of our speciﬁed outcomes were eligible for
inclusion.
• A mixed-treatment comparison meta-analysis was
performed to generate comparative statistics on speciﬁed
outcomes.
Results
• We included data from 19 064 men across one RCT and 57
non-randomised comparative reports.
• Robotic prostatectomy had a lower risk of major
intra-operative harms such as organ injury [0.4% robotic vs
2.9% laparoscopic], odds ratio ([OR] {95% credible interval
[CrI]} 0.16 [0.03 to 0.76]), and a lower rate of surgical
margins positive for cancer [17.6% robotic vs 23.6%
laparoscopic], OR [95% CrI] 0.69 [0.51 to 0.96]). There was
no evidence of a diﬀerence in the proportion of men with
urinary incontinence at 12 months (OR [95% CrI] 0.55 [0.09
to 2.84]). There were insuﬃcient data on sexual dysfunction.
• Surgeon learning rates for the procedures did not diﬀer,
although data were limited.
Conclusions
• Men undergoing robotic prostatectomy appear to have
reduced surgical morbidity, and a lower risk of a positive
surgical margin, which may reduce rates of cancer
recurrence and the need for further treatment, but
considerable uncertainty surrounds these results.
• We found no evidence that men undergoing robotic
prostatectomy are disadvantaged in terms of early
outcomes.
• We were unable to determine longer-term relative
eﬀectiveness.
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Introduction
Radical prostatectomy performed using open or minimally
invasive techniques is the preferred treatment option for men
diagnosed with localised prostate cancer with ∼88 000
procedures carried out in the USA in 2008 [1] and 5500 in the
UK in 2012 [2]. Surgical innovation to reduce blood loss and
hasten recovery led to the introduction of ﬁrstly standard
laparoscopic prostatectomy [3] and then remote laparoscopic
surgery using a master-slave manipulator, known as
robot-assisted or robotic prostatectomy [4], as alternatives to
open surgery. In the USA there has been a predominantly
direct transition from open to robotic prostatectomy, with
44% of procedures performed using the open technique and
53% using the robotic technique in 2008 [5]. By contrast, the
European experience has been a transition from open to the
standard laparoscopic technique followed, mainly in richer
nations, by a second transition to the robot-assisted
procedure; for example in the UK in 2012, 45% of procedures
used the open, 26% the standard laparoscopic and 29% the
robot-assisted techniques [2].
Expert appraisal of the robotic technique suggests quicker
surgeon learning and better ergonomics, although high cost of
the robotic system remains a concern [6,7].When we started
this work there were no high-quality direct comparative
data from individual studies or meta-analyses available to
decide between robot-assisted or standard laparoscopic
prostatectomy as the better alternative to open surgery [8].
These data are needed as the robotic system may only be
aﬀordable if its use beneﬁts individual patients and society in
terms of better cancer control and quicker return to health.
We aimed to address this by estimating diﬀerences in clinical
outcomes between robotic and laparoscopic prostatectomy for
men with localised prostate cancer using a mixed-treatment
comparison meta-analysis. The work formed part of a Health
Technology Assessment (HTA) commissioned by the UK
Government which has been published as a monograph [9].
Methods
Mapping a Care Pathway
A care pathway was deﬁned for men undergoing robotic or
laparoscopic prostatectomy as curative treatment for localised
prostate cancer using published guidance [10,11] and
validated by consensus amongst an expert panel including
patients and clinicians (Fig. 1).
Systematic Literature Review
Eligibility criteria
We speciﬁed robotic prostatectomy as the intervention and
laparoscopic prostatectomy as the comparator.We looked
for reports of randomised control trials (RCTs) and
non-randomised studies comparing outcomes speciﬁed in the Fig
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care pathway. As well as studies directly comparing robotic
and laparoscopic prostatectomy, we included comparisons of
either of the two procedures with open prostatectomy. Our
population was men with localised prostate cancer [clinical
stage (c) T1 or T2] undergoing radical prostatectomy for
cancer cure who were suited to either the robotic or
laparoscopic approach.We excluded studies where >10% of
included men had locally advanced (cT3–cT4) disease.We also
identiﬁed case series involving at least 200 men undergoing
robotic or laparoscopic prostatectomy but only for analysis of
learning-curve eﬀects. There was no language restriction but
we limited our search to between 1st January 1995 and 31st
October 2010.We speciﬁed the following outcome measures
for review:
• Cancer-related: rate of surgical margin positive for cancer;
biochemical (PSA) recurrence; need for further cancer
treatment; and disease-free survival.
• Harms during or shortly after surgery: blood transfusion;
organ injury; anastomotic leak; wound infection; ileus;
venous thrombo-embolic events; bladder neck contracture;
and death.
• Functional: urinary continence and recovery of sexual
function.
• Patient-driven: pain after surgery; time to return to full
activity; and health-related quality of life.
• Descriptors of care: equipment failure; conversion to open
procedure; operating time; duration of catheterisation;
hospital stay; and learning curve.
Information sources
Medline, Medline in Process, Embase, Biosis, the Science
Citation Index and the Cochrane Controlled Trials Register
(CENTRAL) were searched for primary studies, while the
Database of Abstracts of Reviews of Eﬀects (DARE) and the
HTA databases were searched for reports of evidence
syntheses. Reference lists were scanned, an expert panel
consulted, and websites of manufacturers, professional
organisations, and regulatory bodies were checked to identify
additional reports. Abstracts from the European Association of
Urology, AUA and BAUS meetings were searched. Search
strategies are detailed in Table S1.
Study selection and data extraction
Titles and abstracts were screened and the full texts of
potentially relevant reports were assessed for inclusion against
pre-stated criteria by two reviewers, with a third acting as an
arbiter. Data were extracted by three reviewers using a
speciﬁcally designed form [9]. The reviewers checked each
other’s work for errors or inconsistencies. Diverse early harms
of surgery were categorised using the Clavien–Dindo system
by two surgeon reviewers independently, with a third acting as
an arbiter [12]. Organ injury was categorised as Clavien IIIb as
reporting of timing of repair was unclear. The method of
pathological examination of the removed prostate in the
included studies was assessed against the international
consensus standard by a pathologist reviewer [13]. The quality
of included full text English-language studies was assessed by
three pairs of reviewers independently using the Cochrane
risk of bias tool [14] modiﬁed for use with non-randomised
studies and with inclusion of speciﬁc confounders. Risk of bias
for each study was classiﬁed using judgements incorporating
risk of bias domains and individual outcomes into high risk of
bias, low risk of bias or unclear risk of bias categories with any
disagreement between reviewers resolved by consensus.
Data synthesis and analysis
Extracted data were tabulated and summarised. Meta-analysis
was by a mixed-treatment comparison statistical model
incorporating direct comparative studies, and indirect
comparisons against the index procedure of open
prostatectomy. This made maximum use of the available
predominantly non-randomised comparative data in line
with recommended practice [15]. Summary statistics for
dichotomous variables describing the outcomes of robotic
or laparoscopic prostatectomy compared with open
prostatectomy were calculated using the logarithm of the odds
ratios (ORs). Model parameters were estimated within
Bayesian methodology with WinBUGS software, version 1.4.3
[16,17]. A random eﬀects model was used for studies that
compared all three techniques of prostatectomy to adjust for
any correlations between study arms. Variables expressed as
continuous data from direct comparative studies of robotic
and laparoscopic prostatectomy were analysed using mean
and SD values with medians substituted for means if necessary,
and missing SD values separately imputed for each type of
surgery [18]. ORs and their 95% credible intervals (CrIs) were
estimated between robotic and laparoscopic prostatectomy for
each outcome. An OR >1 shows that the event is more likely
to occur after robotic prostatectomy whilst an OR <1 means
that the event is more likely to occur after laparoscopic
prostatectomy. The probability of each OR being diﬀerent
from 1 was calculated, values of P ≥ 0.95 being considered to
indicate statistical signiﬁcance. Finally, an individual estimate
of the probability of the event occurring for each surgical
technique was calculated using a prior distribution for the
probability of occurrence with open radical prostatectomy and
combining that with the OR between robotic and laparoscopic
prostatectomy. The prior distribution was estimated by
applying a normal distribution to the log odds of the
probability of each outcome and using the standard Bayesian
random eﬀects model to calculate its mean and variance. As a
sensitivity analysis the statistical models were run using data
only from studies categorised as having a low risk of bias. In
addition, for surgical margins, we intended to explore
heterogeneity of eﬀects by analysing only data from studies
that reported all key pathological data. Vague prior
distributions were used on the logarithm of the ORs of robotic
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and laparoscopic techniques vs open surgery, the individual
study event rates, and the random eﬀects SD. To assess
publication bias, a funnel plot was constructed for included
direct comparisons reporting the positive margin outcome.
For most outcomes a burn-in period of 20 000 iterations was
adequate to achieve convergence, although a further 100 000
samples were taken for each outcome.
The eﬀect of surgeon learning on outcome was assessed by
categorizing previous experience of participating surgeons and
plotting this against the positive margin rate. In addition, data
on starting level of expertise, rate of learning and deﬁned
expert level were extracted and meta-analysed using a random
eﬀects model to estimate pooled eﬀect and associated
uncertainty expressed as 95% CI.
Results
Details of Included Studies
We identiﬁed one RCT comparing laparoscopic with open
prostatectomy and 57 reports from 53 non-randomised
comparative studies (eight robotic vs laparoscopic, three
robotic vs laparoscopic vs open, 16 robotic vs open and 26
laparoscopic vs open) that fulﬁlled our inclusion criteria
(Fig. 2; Supporting Information References S1–S69; Table S2).
Of the 80 reports excluded because categorisation of patients
by clinical tumour stage was unclear, 69 (86%) had details
enabling contact and 19 replied. This information added one
additional report comparing laparoscopic with open
prostatectomy for inclusion but was received too late for our
planned meta-analysis [19]. The characteristics of included
reports are summarised in Table 1 [S1, S2, S13–68]. A list of
excluded studies with reasons for exclusion is available from
the authors. Data from 19 064 men were used in the
meta-analysis; 6768 underwent robotic radical prostatectomy,
4952 underwent laparoscopic radical prostatectomy, and 7344
underwent open radical prostatectomy. Personal and disease
characteristics of included men were well matched between
robotic and laparoscopic groups (Table 2). The yearly number
of published laparoscopic vs open comparisons peaked in
2007 whilst those for robotic vs open surgery peaked in 2010
(Fig. 3), in line with the sequence of introduction of the
technologies.
Quality Assessment
Overall assessment of risk of bias
The risk of bias was assessed for 48 studies and summary
results for each outcome across the assessed domains are
shown in Fig. 4, with study level assessment in Fig. S4. A total
of 24 reports (50%) were categorised as having a high overall
risk of bias, 13 (27%) as having a low risk and for 11 (23%) the
risk of bias was rated unclear. The single identiﬁed RCT was
judged to be at low risk of bias for sequence generation [S1]
and one further study was judged to be at low risk of bias for
allocation concealment [S2]; all other studies were at high risk
of bias or unclear for these two key domains. Funnel plot
analysis including the six studies directly comparing robotic
with laparoscopic prostatectomy and reporting positive
margin outcome did not suggest publication bias (Fig. 5).
Outcome level assessment for risk of bias
Of the 37 studies reporting positive margin rates or cancer
recurrence, 30 (81%) were considered to be at low risk of bias
for confounding. Of the studies reporting urinary and sexual
function outcomes, 12/23 (52%) and 10/20 (50%), respectively,
were at low risk of bias for blinding and 9/23 (39.1%) and
9/20 (45%), respectively, were at low risk for incomplete
outcome data.
Meta-analysis
The results of the meta-analysis are summarised in Table 3
and Fig. 6. The positive surgical margin rate was signiﬁcantly
lower for robotic (18%) than for laparoscopic prostatectomy
(24%) with an OR (95% CrI) of 0.69 (0.51 to 0.96), P = 0.99.
Fig. 2 Flow chart for the systematic literature review.
2722 titles/abstracts screened
1808 excluded
856 reports excluded:
Not stage T1-T3a
Unknown clinical T stage
Case series laparoscopy
Case series robotic
Conference abstract pre 2006
Not a primary study
No usable data
Not lap or robotic surgery
Secondary publication
Unable to obtain report            
113
80
196
108
121
120
58
41
8
11
914 reports selected for full text assessment
58 reports of 54 studies included:
1 report of 1 randomised controlled trial
57 reports of 53 non-randomised
comparative studies
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Table 1 Summary characteristics of included reports.
Comparison Country of Origin Number of centres Number of participants recruited
Robotic Laparoscopic Open
Robotic vs laparoscopic
Gosseine 2009 [S17] France 1 122 125
Hu 2006 [S18] USA 1 322 358
Joseph 2007 [S19] France and USA 2 754 800
Joseph 2005 [S20] USA 1 50 50
Menon 2002 [S13] France 1 50 48
Rozet 2007 [S21] France 1 133 758
Sundaram 2004 [S22] USA 1 10 10
Trabulsi 2008 [S23] USA 1 50 190
Robotic vs laparoscopic vs open
Ball 2006 [S14] USA 1 82 124 135
Bolenz 2010 [S15] USA 1 262 211 156
Bolenz 2009 [S24] (secondary to Bolenz 2010) USA 1 264 220 162
Drouin 2009 [S16] France Not reported 71 85 83
Robotic vs open
Barocas 2010 [S25] USA 1 1413 491
Kordan 2010 [S26] (secondary to Barocas 2010) USA 1 830 414
Chan 2008 [S27] (secondary to Barocas 2010) USA 1 660 340
Carlsson 2010 [S28] Sweden 1 1253 485
Doumerc 2010 [S29] Australia Not reported 212 502
Ficarra 2009 [S30] Italy 1 103 105
Fracalanza 2008 [S31] Italy 1 35 26
Krambeck 2009 [S32] USA 1 294 588
Loeb 2010 [S33] USA Not reported 152 137
Malcolm 2010 [S34] USA 1 447 135
Miller 2007 [S35] USA 1 42 120
Nadler 2010 [S36] USA 1 50 50
Ou 2009 [S37] Taiwan 1 30 30
Rocco 2009 [S38] Italy 1 120 240
Schroeck 2008 [S39] USA 1 362 435
Tewari 2003 [S40] USA 1 200 100
Truesdale 2010[S41] USA 1 99 217
White 2009 [S42] USA 1 50 50
Laparoscopic vs open
Al-Shaiji 2010 [s43] Canada 1 70 70
Anastasiadis 2003 [S44] France 1 230 70
Artibani 2003 [S45] Italy 2 71 50
Bhayani 2003 [S46] USA 1 33 24
Brown 2004 [S47] USA 1 60 60
Dahl 2009 [S48] USA 1 104 102
Dahl 2006 S49 (secondary to Dahl 2009) USA 1 286 714
Fornara 2004 [S50] Germany 1 32 32
Ghavamian 2006 [S51] USA 1 70 70
Greco 2010 [S52] Italy 1 150 150
Guazzoni 2006 [S1] Italy 1 60 60
Jacobsen 2007 [S53] Canada 1 57 148
Jurczok 2007 [S54] Germany 1 163 240
Kim 2007 [S55] Korea 1 30 45
Lama 2009 [S56] Chile 1 56 59
Martorana 2004 [S57] Italy 1 50 50
Namiki 2005 [S58] Japan 4 45 121
Namiki 2006 [S59] Japan 4 64 283
Poulakis 2007 [S60] Germany 1 204 70
Raventos 2007 [S61] Spain Not reported 105 75
Remzi 2005 [S62] Austria 1 80 41
Salomon 2002 [S63] France 4 155 151
Silva 2007 [S64] Brazil 2 90 89
Soderdahl 2005 [S65] USA 1 116 186
Soric 2004 [S66] Croatia 1 26 26
Terakawa 2008 [S67] Japan 1 137 220
Touijer 2007 [S2] USA 1 485 692
Wagner 2007 [S68] USA 1 75 75
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Uncertainty surrounding this estimate was increased when
only studies with a low risk of bias were analysed with the CrI,
including the ﬁnding of no diﬀerence; OR (95% CrI) of 0.73
(0.29 to 1.75), P = 0.78 (Table 4 [S1, S13, S16, S19, S21–S23,
S25, S29–S33, S36–S40, S42, S44, S45, S47, S49, S50, S52–S57,
S60, S62–S64, S66–S68]). Methods of pathological analysis
reported by included studies showed high variability and
non-compliance with recommended protocols, with no two
studies reporting the same method for ascertainment of
positive margin status. It was therefore not possible to
undertake the planned sensitivity analysis restricted to studies
using a standard method. Duration of surgery was, on average,
12 min shorter for the robotic procedure (P = 0.99) but
diﬀering deﬁnitions made accuracy of this result highly
uncertain. Men had a lower risk of major harms occurring
during or immediately after robotic prostatectomy, such as
injury to adjacent organs and leakage from the vesico-urethral
anastomosis, but these events were uncommon. Other
outcomes, including risk of biochemical recurrence at 12
months and rates of urinary incontinence, showed no
Table 2 Summary description of patient cohort characteristics extracted from the included studies.
Robotic Laparoscopic Open
N 6768 4952 7344
Median (IQR) age, years 61 (59–62) 62 (60–64) 63.0 (60–65)
Clinical (c) stage, n (%)
cT1 4380 (64.7) 3257 (65.7) 3956 (53.9)
cT2 1743 (25.7) 1312 (26.5) 2194 (29.9)
cT3 58 (0.9) 26 (0.5) 148 (2.0)
cT4 1 (0.01) 8 (0.2) 0 (0)
Missing/Unknown* 586 (8.7) 349 (7.1) 1046 (14.2)
Preoperative core biopsy pathological Gleason score, n (%)
≤6 2179 (32.2) 989 (20.0) 2389 (32.5)
7 949 (14.0) 429 (8.7) 1574 (21.4)
8–10 198 (2.9) 54 (1.1) 333 (4.5)
Missing/Unknown* 3442 (50.9) 3480 (70.3) 3048 (41.5)
Median (IQR) preoperative PSA, ng/mL 6.3 (5.4–7.1) 7.2 (6.3–8.6) 7.9 (6.0–9.3)
Pathological tumour stage, n (%)
pT0 7 (0.1) 6 (0.1) 22 (0.3)
pT1 0 (0) 29 (0.6) 25 (0.3)
pT2 2060 (30.4) 2373 (47.9) 4246 (57.8)
pT3 571 (8.4) 669 (13.5) 1368 (18.6)
pT3/4* 23 (0.3) 45 (0.9) 76 (1.0)
pT4 7 (0.1) 17 (0.3) 33 (0.4)
Missing/Unknown* 4203 (62.1) 1710 (34.5) 1574 (21.4)
Postoperative whole prostate pathological Gleason score, n (%)
≤6 1200 (17.7) 485 (9.8) 1666 (22.7)
7 1110 (16.4) 415 (8.4) 1634 (22.3)
8–10 161 (2.4) 49 (1.0) 379 (5.2)
Missing/Unknown† 4297 (63.5) 4003 (80.8) 3665 (49.9)
*pT3 and pT4 not diﬀerentiated in two study reports. †Either owing to missing, unsuitable or non-reported data. IQR,
interquartile range.
0
1
2
3
4
5
6
7
8
9
2002 2003 2004 2005 2006 2007 2008 2009 2010
N
um
be
r o
f p
ub
lic
at
io
ns
Year of publication
Robotic versus
laparoscopic
Robotic versus
laparoscopic
versus open
Robotic versus
open
Laparoscopic
versus open
Fig. 3 Year of publication of included studies
according to comparison.
Systematic review and comparative meta-analysis of outcomes from robotic and laparoscopic prostatatectomy
© 2013 The Authors
BJU International © 2013 BJU International 803
diﬀerence. Rates of these outcomes reported by individual
studies are given in Table S1.We were unable to perform a
meta-analysis for a number of pre-speciﬁed outcomes, such as
sexual function and those describing patient experience,
mainly owing to a lack of data and the use of widely varying
outcome measurement tools (Table 5).
Learning Curve
We used positive surgical margin rate as the key outcome to
assess the eﬀect of increasing surgeon experience in line with
the main meta-analysis. In general, available data assessing
surgeon learning was limited and often not in a form suited to
meta-analysis with variable descriptive categorisation of
surgeon prior experience. Regression modelling using data
from studies included in the main meta-analysis showed no
evidence of outcome trends with increasing experience (R2 <
0.02%; Fig. 7). Extending study eligibility criteria to include
case series identiﬁed four reports of robotic prostatectomy
[S3–S6] and six reports of laparoscopic prostatectomy
(Table 6) [S7–S12]. Two studies [S7,S9] only reported a
mathematical shape to the learning curve, preventing
extraction of relevant variables. All studies reported a decrease
in positive surgical margin rates with increasing surgeon
experience except one [S7], which reported a constant low rate
Fig. 4 Summary chart of the proportion of the 47 studies assessed for risk of bias showing low, high or unclear risk of bias for methodological
constructs and meta-analysed outcomes.
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
A priori analysis plan
A priori protocol
Other bias
Free of selective reporting efficacy
Free of selective reporting sexual dysfunction
Free of selective reporting urinary dysfunction
Free of selective reporting peri-op safety
Incomplete outcome data efficacy
Incomplete outcome data sexual dysfunction
Incomplete outcome data urinary dysfunction
Incomplete outcome data peri-op safety
Blinding efficacy
Blinding sexual dysfunction
Blinding urinary dysfunction
Blinding peri-op safety
Confounding efficacy
Confounding sexual dysfunction
Confounding urinary dysfunction
Confounding peri-op safety
Allocation concealment
Sequence generation
Low
High
Unclear
Fig. 5 Funnel plot of studies directly comparing robotic with laparoscopic
prostatectomy and reporting positive surgical margin outcome.Vertical
axis shows variance measured by SE of the logarithm of the OR and the
horizontal axis shows the OR with values <1 favouring robotic
prostatectomy.Vertical blue line represents central estimate, with sloped
lines representing 95% CrI.
0
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for laparoscopic prostatectomy. The mean positive margin
rates for both procedures fell from 26% at case one to 15% by
case 250, and to 12% by case 1000. There was no evidence that
this observed rate of learning diﬀered between robotic and
laparoscopic procedures with a mean (95% CI) diﬀerence of
−0.02 [(−0.16 to 0.12), P = 0.76].
Discussion
Our mixed-treatment comparison meta-analysis made best
use of the available, predominantly non-randomised
comparative data to estimate the relative beneﬁts and harms of
robotic and laparoscopic prostatectomy as alternatives to open
surgery. Imprecision and uncertainty surrounding these
estimates mean that our ﬁndings should be interpreted
cautiously. The signiﬁcant reduction in the rate of a surgical
margin positive for cancer after robotic prostatectomy is
important since it is likely to be linked to a lower risk of
disease recurrence and the need for further cancer treatment
in the longer term [19]; however, the limited data from
included studies did not suggest lower rates of biochemical
(PSA) cancer recurrence after robotic prostatectomy. The
lower risk of major harms during and immediately after
robotic prostatectomy suggests a superior safety proﬁle,
although these events were infrequent. There was no evidence
of lower rates of urinary incontinence but we could not draw
any conclusions about sexual dysfunction because of a lack of
usable data. There was no evidence to suggest that surgeon
learning rates were faster using the robotic system, although
data were limited. The relative eﬀects on patient experience
and cancer-free survival remain unknown. Overall, we found
no evidence that robotic prostatectomy was inferior to
standard laparoscopic prostatectomy for treatment of men
with localised prostate cancer.
We pre-deﬁned the search strategy and outcomes of interest
and used systematic, exhaustive search and data extraction
techniques to ensure that all available data were identiﬁed and
included in our meta-analysis.We may have missed usable
data, although communication with authors of studies where
fulﬁlment of our inclusion criteria was uncertain showed that
only one of these studies was suitable.We speciﬁed a cut-oﬀ
date for our search of 31st October 2010 to allow time and
resources for data extraction, risk of bias assessment and
meta-analysis which underpinned the completion of a careful
and high-quality evidence review.We performed an updated
search of literature published between November 2010 and
December 2011 identifying a further 15 comparative studies
meeting our inclusion criteria, including one RCT which
found as a secondary outcome a positive margin rate of 6/60
(10%) after laparoscopic prostatectomy and 8/52 (15%) after
robotic prostatectomy [20].
Table 3 Results of the mixed-treatment comparison meta-analysis illustrating the probability of clinical outcomes for robotic prostatectomy and
laparoscopic prostatectomy.
Outcome Predicted probability of event OR 95% CrI Probability of outcome
RP LP P
Cancer
Positive surgical margin 0.176 0.236 0.69 0.51 to 0.96 0.99
Biochemical recurrence 0.087 0.097 0.89 0.24 to 3.34 0.59
Procedural
Change to another intervention 0.003 0.009 0.28 0.03 to 2.00 0.89
Mean operating time (minutes) 225 238 −12.4 −16.5 to −8.1 0.99
Peri-operative harms
Clavien I 0.021 0.041 0.48 0.15 to 1.55 0.90
Infection 0.008 0.011 0.75 0.18 to 3.35 0.66
Anastomotic leak 0.010 0.044 0.21 0.05 to 0.76 0.99
Clavien II 0.039 0.072 0.52 0.22 to 1.18 0.94
Blood transfusion 0.035 0.050 0.71 0.31 to 1.62 0.78
Ileus 0.011 0.024 0.46 0.12 to 1.51 0.92
Deep venous thrombosis 0.006 0.002 2.67 0.26 to 50.3 0.19
Clavien IIIa 0.005 0.013 0.36 0.03 to 2.57 0.85
Clavien IIIb* 0.009 0.036 0.25 0.06 to 0.92 0.98
Organ injury 0.004 0.029 0.16 0.03 to 0.76 0.99
Clavien IV 0.006 0.008 0.76 0.14 to 3.44 0.64
Clavien V 0.000 0.002 0.00 0.00 to 0.12 0.99
Postoperative harms
Bladder neck contracture 0.010 0.021 0.48 0.09 to 2.93 0.81
Urinary incontinence 0.045 0.079 0.55 0.09 to 2.84 0.60
RP, robotic prostatectomy; LP, laparoscopic prostatectomy. Clavien I = deviation from standard care not needing intervention; Clavien II = deviation from standard care needing
non-surgical intervention; Clavien IIIa = deviation from standard care needing surgical intervention without general anaesthetic; Clavien IIIb = deviation from standard care needing
surgical intervention under general anaesthetic; Claivien IV = deviation from standard care with organ failure needing intensive care; Clavien V = death of patient. *Includes organ
injury.
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We chose to exclude case series since meta-analysis of such
studies are more likely to introduce selection bias stemming
from lack of control of patient proﬁles across diﬀerent
societies and institutions. They are also less likely to address
key outcomes, and are wasteful of research resources [21].
Personal and disease characteristics for included men were
equivalent between the two procedures and reﬂected those of
men undergoing radical prostatectomy in the UK [22],
suggesting that our ﬁndings were reliable and generalisable,
and that potential confounders such as preoperative PSA value
and Gleason score were balanced. To address confounding by
disease stage, we excluded studies involving >10% of men with
locally advanced (cT3) disease, as their greater risk of positive
margin and disease persistence would have a disproportionate
eﬀect on outcomes if there was imbalance between study
groups. This appeared eﬀective since >80% of included studies
contributing to positive margin outcome were categorised as
at low risk of confounder bias.We made concerted eﬀorts to
prevent the inclusion of duplicate data resulting from multiple
reports of the same cohort but it is possible that some
instances were missed. Included studies were generally of low
quality and data too few for meta-analysis of some important
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Fig. 6 Summary of the clinical effect sizes (OR
and 95% CrI) from meta-analyses. To improve
visual display, the upper CrI has been
truncated to 5.0. Estimates from only low risk of
bias (RoB) studies are shown.
Fig. 7 Proportion of positive surgical margins with increasing experience
of operating surgeon in included studies (learning curve). Dashed line is
the predicted linear relationship for laparoscopic studies and the solid
line is the predicted linear relationship for robotic studies.
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outcomes including sexual function, postoperative pain, and
quality of life.
We included studies that used either contemporaneous or
sequential comparative cohorts since we considered that such
diﬀerences in design would not result in a particular direction
of bias but rather that the overall quality of each included
study was of greater importance [23]. An additional factor
for this review was the likelihood that surgeons had less
experience with the newer technique than the previous
technique with which it was compared. Four of the eight
robotic vs laparoscopic comparisons gave descriptive
information on this issue with all stating that the surgeons
were experienced in laparoscopic prostatectomy and had
completed a structured training in robotic prostatectomy
[S13–S16]. Publication bias for direct comparisons of the
newer technique (robotic) against the alternative
(laparoscopic) might be expected in the early phase of
technology assessment which may be driven by individual
surgeon enthusiasm or commercial pressures, but a restricted
funnel plot analysis did not suggest such bias for reporting of
positive surgical margins in line with previous reviews
[24–26].
Included studies were of short duration and data regarding
disease-free survival were not available. A pathological ﬁnding
of a surgical margin positive for cancer was therefore used as
the measure by which to judge relative eﬀectiveness.
Achievement of a negative margin is considered to be an
immediate marker of successful surgery, both in terms of
Table 4 Patient cohort characteristics of included studies providing data for positive surgical margin outcome meta-analysis with summary results.
Study Positive surgical margins, n/N (%)
Robotic Laparoscopic Open
Anastasiadis 2003 [S44]* 61/230 (26.5) 20/70 (28.6)
Artibani 2003 [S45] 21/71 (30) 12/50 (24)
Barocas 2010 [S25] 281/1413 (19.9) 148/491 (30.1)
Brown 2004 [S47] 10/59 (16.9) 12/60 (20)
Dahl 2006 [S49] 43/286 (15) 124/714 (17.4)
Doumerc 2010 [S29] 45/212 (21.2) 84/502 (16.7)
Drouin 2009 [S16]* 12/71 (16.9) 16/85 (18.8) 15/83 (18.1)
Ficarra 2009 [S30] 35/103 (34) 21/105 (21)
Fornara 2004 [S50] 5/32 (16) 7/32 (22)
Fracalanza 2008 [S31] 10/35 (28.6) 6/26 (23)
Greco 2010 [S52]* 12/150 (8) 17/150 (11.3)
Guazzoni 2006 [S1]* 16/60 (26.7) 13/60 (21.7)
Jacobsen 2007 [S53] 22/67 (38) 60/148 (40)
Joseph 2007 [S19] 99/754 (13.1) 246/800 (30.75)
Jurczok 2007 [S54] 63/163 (38.8) 104/240 (43.6)
Kim 2007 [S55] 11/30 (36.7) 11/45 (24.4)
Krambeck 2009 [S32] 46/294 (15.6) 100/588 (17.2)
Lama 2009 [S56] 16/56 (28.6) 21/59 (35.6)
Loeb 2010 [S33] 22/152 (14.5) 25/137 (18.2)
Martorana 2004 [S57] 12/50 (24) 13/50 (26)
Menon 2002 [S13] 7/40 (17.5) 10/40 (25)
Nadler 2010 [S36] 5/50 (10) 12/50 (24)
Ou 2009 [S37] 15/30 (50) 6/30 (20)
Poulakis 2007 [S60] 15/72 (20.8) 16/70 (22.8)
Remzi 2005 [S62] 10/39 (25.6) 8/41 (19.5)
Rocco 2009 [S38] 26/120 (22) 60/240 (25)
Rozet 2007 [S21] 26/133 (19.5) 21/133 (15.8)
Salomon 2002 [S63] 32/155 (20.6) 30/151 (19.9)
Schroeck 2008 [S39] 106/362 (29) 122/435 (28)
Silva 2007 [S64] 22/90 (24.44) 37/89 (41.57)
Soric 2004 [S66] 6/26 (23) 3/26 (11.5)
Sundaram 2004 [S22] 2/10 (20) 2/10 (20)
Terakawa 2008 [S67] 54/137 (39.4) 52/220 (23.6)
Tewari 2003 [S40] 18/200 (9) 23/100 (23)
Trabulsi 2008 [S23] 3/50 (6) 35/190 (18)
Wagner 2007 [S68] 7/75 (9) 14/75 (19)
White 2009 [S42]* 11/50 (22) 18/50 (36)
Predicted probability of event 0.18 0.24 0.24
OR (95% CrI); probability outcome favours robotic prostatectomy All studies
Low risk of bias studies only
0.69 (0.51 to 0.96);0.99
0.73 (0.29 to 1.75);0.78
*Study included in the low risk of bias meta-analysis. OR, odds ratio.
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cancer control and surgical quality, as a positive margin
increases the risk of disease recurrence and the need for
further cancer treatment [27,28]. It is possible that variability
and lack of consistency in the reporting of pathological
examination techniques led to a systematic bias in the
detection of positive margins, in particular for studies using a
non-contemporary control group, but we found insuﬃcient
data to assess this.We chose not to re-analyse positive margin
rate according to pathological stage given our limited
inclusion of men with cT3 disease and concerns regarding
analysis of sub-groups deﬁned by non-baseline characteristics.
In line with best practice and to encompass all the factors
described above, we individually assessed each included study
for risk of bias using an established tool and multiple
independent raters [14]. The positive margin re-analysis using
low risk of bias study data showed a similar point estimate of
eﬀect but increased the degree of uncertainty to include the
ﬁnding of no diﬀerence. For organ injury, the result showed
an increased likelihood that robotic prostatectomy was safer
with less uncertainty. For other outcomes, low risk of bias
studies were too few for meaningful meta-analysis. Although
the main limiting factor for these sensitivity analyses was low
study quality there may also be inadequacies of the tool used
[23] and the ﬁndings reinforce the need for methodological
research [29].
We identiﬁed four further systematic reviews and one
published as three papers, contemporary to our own which
used diﬀerent meta-analytic techniques [24,26,30–33]. All ﬁve
reviews found that positive margin rate was the only cancer
outcome with suﬃcient data for meta-analysis and, although
central estimates of risk all favoured robotic prostatectomy,
eﬀect size and degree of uncertainty varied, with only our
results and those of Tewari et al. [26] showing statistical
signiﬁcance (Table 7 [24,26,30–33]). The aim of any
meta-analysis is to calculate the most accurate and precise
estimate of the true absolute or relative value for any outcome
from the data deemed eligible for inclusion. It continues to be
a challenge to achieve this without high-quality randomised
controlled data and a number of statistical models have
evolved to make use of non-randomised data with reduced
uncertainty.We considered that a mixed-treatment
comparison including indirect comparisons was the
most appropriate model, in line with guidance from
evidence-synthesis organisations [14,34–37]. This achieved a
large sample size whilst maintaining the advantage of
estimation of outcomes as relative diﬀerences rather than
crude absolute rates to minimise eﬀects of selection and
reporting bias. The method also captured diﬀerent transitions
of surgeon experience, such as that from open to robotic
prostatectomy and open to laparoscopic to robotic, and
avoided procedural bias that could arise from only including
Table 5 Pre-planned outcome variables not included in meta-analysis with reasons.
Outcome variable Number of studies
reporting
Reason for no meta-analysis Comment
Harms during and soon after surgery
Death 10 Too few events reported
Hernia 3 No comparative data
Pulmonary embolism 5 Event rate too low
Blood loss volume 29 Diverse methods of measurement and
wide variation
Quantiﬁed as transfusion rate
Diverse postoperative complications 31 Varying terminology wide diversity Categorised post hoc according to Clavien–Dindo [11]
Cancer-related
Disease-free survival 0 No data in included studies
Need for further cancer treatment 1 No comparative data
Local recurrence 1 No comparative data
Metastatic recurrence 1 No comparative data
Functional
Sexual dysfunction 19 Diversity of outcomes and types of data One comparative study favoured robotic and one favoured
laparoscopic
Faecal incontinence 3 Diverse deﬁnitions and timing of
outcome measurement
Treatment of functional harms 1 No comparative data
Patient-driven
Postoperative pain Not reported by included studies
Changes to quality of life 5 Diversity of outcomes and types of data Insuﬃcient data for comparison
Return to productivity 3 Data not evaluable
Descriptors of care
Duration of catheterisation 23 Diverse policies and outcome measures Of four direct comparative studies, two favoured robotic and
two laparoscopic
Hospital stay 28 Diverse methods of measurement Of four direct comparative studies, two favoured robotic and
two laparoscopic
Early mobilisation 3 No comparative data
Oral intake 4 No comparative data
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publications from centres able to perform both robotic and
laparoscopic techniques. For positive margin outcome,
random eﬀects meta-analyses using only direct comparative
studies all gave broadly similar results but had small total
sample size which varied according to diﬀerent judgements on
study eligibility [24,30–33] (Fig. 7). Tewari et al. [26] expanded
total sample size further by including case series of both
techniques and used propensity-matching to control for
diﬀerences in baseline characteristics.Whilst this gave a more
precise estimate of diﬀerence in positive margin rate it may
Table 6 Summary of learning curve measures in cases series.
Study Reported
outcomes
N Robotic
measured
outcome
Laparoscopic
measured
outcome
Other information
reported in study
Secin 2010 [S11] Positive margin rate 6274 Case 1: 24%
Case 250: 19%
Hong 2010 [S3] Positive margin rate 469 Case 1: 27%
Case 200: 25%
Case 400: 21%:
Linear trend
Tewari 2010 [S6] Positive margin rate 1340 Case 1: 9%
Case 100: 7%:
McNeill 2010 [S9] Positive margin rate
Operation time
Complications
300 Case 1–50: 27%
Case 251–300: 14.7%
Case 1: 200 min
Case 200: 140 min
Case 1: 29%
Case 250: <1%
Log linear trend
Samadi 2010 [S5] Positive margin rate 1181 Case 1: 8.5%
Case 590: 4.3%
Rodriguez 2010 [S10] Positive margin rate 400 Case 1: 32%
Case 400: 13.3%
Jaﬀe 2009 [S4] Positive margin rate
Operation Time
278 Case 1–12: 58%
Case 12–189: 23%
Case 278: 9%
Case 1–12: 250 min
Case 12–189: 165 min
Case 278: 134 min
Eden 2009 [S7] Positive margin rate
Complications
Blood loss
Normal sexual function
Operation time
1000 Series mean: 13.3%
Series mean: 200 mL
Case 1: 23%
Case 1000: 86%
Series mean: 177 min
No trend noted
No trend noted
Stabilised after 200 cases
Stabilised after 700 cases
Stabilised after 200 cases
Vickers 2009 [S12] Biochemical (PSA) recurrence 4702 Case 10: 16%
Case 250: 15.5%
Case 750: 8.2%
Martinez-Pineiro 2006 [S8] Positive margin rate
Blood transfusion rate
Operation time
604 Case 1: 25%
Case 600: 7%
Series mean: 201 min
Decreased signiﬁcantly by 101 cases
Stabilised by 200 cases
Table 7 Estimates of relative outcomes for robotic vs laparoscopic prostatectomy from contemporary meta-analyses.
Study Type of
meta-analysis
Expression
of difference
Positive margin* Early complications* Urinary incontinence
at 12 months*
Median (CI) number
of patients
Median (CI) number
of patients
Median (CI) number
of patients
Present paper Mixed-treatment comparison OR 0.69 (0.51 to 0.96) N = 7186 0.16 (0.06 to 0.76) N = 5383† 0.55 (0.09 to 2.84) N = 2322
Ho et al. (2011) [31] Random-eﬀects RR 0.89 (0.66 to 1.19) N = 1061 0.85 (0.5 to 1.44) N = 1845 1.08 (0.99 to 1.18) N = 400
Flattery et al. (2011) [24] Random-eﬀects RR 0.93 (0.70 to 1.22) N = 1114 0.96 (0.53 to 1.73) n = 1911 1.09 (1.02 to 1.14) N = 512
Tewari et al. (2012) [26] Pairwise with propensity
adjustment
OR 0.80 (0.76 to 0.85‡) N = 62 130 0.68 (0.62 to 0.74‡) N = 30 698 N/A
Novara et al. (2012)
[30,32,33]
Fixed or random-eﬀects OR 0.89 (0.64 to 1.23) N = 2514 0.71 (0.37 to 1.37) N = 1720 0.42 (0.23 to 0.78) N = 738
RR, relative risk. *Values <1 favour robotic prostatectomy. †Organ injury only. ‡Additional data obtained from the authors.
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not have adequately controlled for risk of selection bias and
confounding [21,29,38]. In terms of other outcomes we reported
comparative data for individual complications speciﬁcally
recorded in the source material, whilst in the other studies they
were grouped together using varying criteria preventing any
comment of the relative accuracy of estimates. One review found
a signiﬁcantly higher rate of continence for robot-assisted than
for standard laparoscopic prostatectomy at 1 year [30], whilst the
other three studies reporting this outcome, including our own,
found no evidence of a diﬀerential risk between the two
procedures [24,26]; this may have resulted from varying study
inclusion criteria. For the seeker of evidence, these ﬁve
meta-analyses can be thought of as sensitivity analyses exploring
the impact of diﬀerent methodological judgments. The
consistency in the direction of relative diﬀerence in positive
margin rate and the lack of any outcomes assessed as inferior
after robotic prostatectomy across the studies are reassuring, but
interpretation of any meta-analysis based on non-randomised
data should always be cautious [29].
Our ﬁnding of no evidence for diﬀerential surgeon learning
between the two techniques diﬀers from other publications
[39]. This may be attributable to the use of positive margin
rates rather than operating time or blood transfusion rates as a
competency marker or possibly to the limited nature of the
data available. Our results suggest that the individual surgeon’s
rate of learning is the dominant factor rather than the
technology used [40].
The need for radical prostatectomy is likely to be maintained
or to increase over the next 5 years with PSA-driven higher
detection rates for localised prostate cancer, although new less
invasive treatments may expand the choice of management
[41]. Our results will help guide patients, clinicians and
healthcare managers in the choices they make regarding the
implementation and use of robotic prostatectomy but, given
uncertainty around the meaning of the data, cautious
interpretation is emphasised and other sources of evidence,
particularly contemporary meta-analyses should be
considered. It seems unlikely that a large robustly designed
RCT comparing robotic with laparoscopic prostatectomy will
be carried out (a feasibility study was recently unsuccessful in
the UK) but well-designed prospective multicentre cohort
studies with longer-term outcome assessment as well as
independent veriﬁcation of baseline data and outcome should
be possible.Without such studies assessment of the value of
costly new technology to patients and healthcare systems such
as the UK NHS will continue to be imperfect.
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